secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001193125-25-329511
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics elects Vikram Karnani as Class II director effective Dec 22, 2025
--------------------------------------------------------------------------------

- Vikram Karnani elected to the Board as an independent director; term expires at 2028 Annual Meeting.
- Received option to purchase 59,665 shares at $20.78/share, vesting monthly over three years.
- Will receive annual cash compensation of $45,000 plus standard equity grants under non-employee director plan.
- No family relationships or material transactions with the Company; standard indemnification agreement entered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525329511/0001193125-25-329511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525329511/dyn-20251222.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-329511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer